October 13th 2025, 3:54pm
Brittney Nichols highlights the need for early detection and stresses that lung cancer is not only caused by smoking; anyone can develop the disease.
October 6th 2025, 8:00pm
In EGFR-mutated non-small cell lung cancer Tagrisso with pemetrexed and chemotherapy was associated with an improvement in survival.
October 1st 2025, 1:00pm
Dr. Mary B. Beasley discusses evolving role of pathologists in lung cancer care, highlighting how emerging technologies may shape the future of the field.
September 26th 2025, 8:00pm
Ibtrozi may become the new standard for ROS1-mutated lung cancer, with phase 2 data showing safer, longer-lasting benefits for patients.
September 25th 2025, 8:00pm
Dr. Jacob A. Sands shares how patients with lung cancer can interpret clinical trial results and how these findings translate to treatment decisions.
September 16th 2025, 8:00pm
Dr. Joshua K. Sabari sat down with Terri Conneran at the 2025 World Conference on Lung Cancer for a conversation on the importance of biomarker testing.
September 15th 2025, 1:00pm
Dr. Joshua Sabari spoke with advocate Chris Conneran on his journey from caregiver to champion for KRAS-mutant cancer patients and families.
September 14th 2025, 2:00pm
Lutathera demonstrated antitumor activity in patients with metastatic bronchopulmonary neuroendocrine tumors.
September 13th 2025, 6:00pm
For patients with MET exon 14-altered NSCLC, Tepmetko was associated with frequent side effects, although the safety profile is considered manageable.
September 12th 2025, 8:00pm
Dr. Josh Sabari and Max Doppelt explore challenges in trial enrollment and the potential of emerging therapies to offer hope for patients diagnosed today.
Inlexzo Offers New Option for Patients With Unresponsive Bladder Cancer
Managing Lynch Syndrome
New Directions in Treatment for Patients With GIST
More Patients Are Living Beyond Liver Cancer Thanks to Expanding Care